+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

2019 Pulmonary Tuberculosis Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768029
  • Report
  • 157 pages
  • VPA Research
1 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • IQVIA Holdings Inc
  • Johnson & Johnson
  • LegoChem Biosciences Inc
  • Otsuka Holdings Co Ltd
  • MORE
The global clinical trial report- “2019 Pulmonary Tuberculosis Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Pulmonary Tuberculosis. It presents in-depth analysis of Pulmonary Tuberculosis clinical trials across markets and companies. The research work is for providing complete understanding into trends in Pulmonary Tuberculosis.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Pulmonary Tuberculosis clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Pulmonary Tuberculosis

The research work is prepared through extensive and continuous research on Pulmonary Tuberculosis trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Pulmonary Tuberculosis patients are identified
  • The report includes panorama of Pulmonary Tuberculosis clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Pulmonary Tuberculosis clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • IQVIA Holdings Inc
  • Johnson & Johnson
  • LegoChem Biosciences Inc
  • Otsuka Holdings Co Ltd
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Pulmonary Tuberculosis Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Pulmonary Tuberculosis Clinical Trials by Region
2.2.2 Average Enrollment of Pulmonary Tuberculosis Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Pulmonary Tuberculosis Treatment, 2019

3. Region wise Pulmonary Tuberculosis Clinical Trials
3.1 Asia Pacific Pulmonary Tuberculosis Clinical Trials by Country
3.2 Europe Pulmonary Tuberculosis Clinical Trials by Country
3.3 North America Pulmonary Tuberculosis Clinical Trials by Country
3.4 Middle East and Africa Pulmonary Tuberculosis Clinical Trials by Country
3.5 South and Central America Pulmonary Tuberculosis Clinical Trials by Country

4. Pulmonary Tuberculosis Clinical Trial Trends
4.1 Start Year wise Pulmonary Tuberculosis Clinical Trials
4.2 Phase wise Pulmonary Tuberculosis Clinical Trials
4.3 Trial Status wise Pulmonary Tuberculosis Clinical Trials
4.4 Trial Type wise Pulmonary Tuberculosis Clinical Trials

5. Pulmonary Tuberculosis Average Enrollment Trends
5.1 Average Enrollment in Pulmonary Tuberculosis Trials by Year
5.2 Average Enrollment in Pulmonary Tuberculosis Trials by Phase
5.3 Average Enrollment in Pulmonary Tuberculosis Trials by Status
5.4 Average Enrollment in Pulmonary Tuberculosis Trials by Type of Trial

6. Companies Participating in Pulmonary Tuberculosis Clinical Trials
6.1 Pulmonary Tuberculosis Trials by Sponsor Type
6.2 Pulmonary Tuberculosis Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Pulmonary Tuberculosis Trials- Phase 1
7.2 Pulmonary Tuberculosis Trials- Phase 2
7.3 Pulmonary Tuberculosis Trials- Phase 3
7.4 Pulmonary Tuberculosis Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Pulmonary Tuberculosis Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Pulmonary Tuberculosis Clinical Trials and Enrolment
Figure 5: Europe - Country wise Pulmonary Tuberculosis Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Pulmonary Tuberculosis Clinical Trials and Enrolment
Figure 7: North America - Country wise Pulmonary Tuberculosis Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Pulmonary Tuberculosis Clinical Trials and Enrolment
Figure 9: Pulmonary Tuberculosis Clinical Trials by Phase
Figure 10: Pulmonary Tuberculosis Clinical Trials by Trial Status
Figure 11: Pulmonary Tuberculosis Clinical Trials by Type
Figure 12: Pulmonary Tuberculosis Clinical Trials by Sponsor Type
Figure 13: Pulmonary Tuberculosis Clinical Trials by Leading Sponsors
Figure 14: Pulmonary Tuberculosis Average Enrollment by Phase
Figure 15: Pulmonary Tuberculosis Average Enrollment by Trial Status
Figure 16: Pulmonary Tuberculosis Average Enrollment by Type
Figure 17: Pulmonary Tuberculosis- Average Enrolment by Type of Sponsors
Figure 18: Pulmonary Tuberculosis- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Pulmonary Tuberculosis Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Pulmonary Tuberculosis Clinical Trials and Enrolment
Table 5: Europe - Country wise Pulmonary Tuberculosis Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Pulmonary Tuberculosis Clinical Trials and Enrolment
Table 7: North America - Country wise Pulmonary Tuberculosis Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Pulmonary Tuberculosis Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Pulmonary Tuberculosis Average Enrollment by Phase
Table 15: Pulmonary Tuberculosis Average Enrollment by Trial Status
Table 16: Pulmonary Tuberculosis Average Enrollment by Type
Table 17: Pulmonary Tuberculosis- Average Enrolment by Type of Sponsors
Table 18: Pulmonary Tuberculosis- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AstraZeneca Plc
  • Cadila Pharmaceuticals Ltd
  • Chongqing Zhifei Biological Products Co Ltd
  • GlaxoSmithKline Plc
  • IQVIA Holdings Inc
  • Johnson & Johnson
  • LegoChem Biosciences Inc
  • Otsuka Holdings Co Ltd
  • Sanofi
  • Sequella Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4768029
Adroll
adroll